Close

Novotech

Orexo announces termination of OX-CLI and OX-ESI programs

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

- Advertisement -

Orexo and Janssen Pharmaceuticals, formerly Ortho-McNeil-Janssen Pharmaceuticals, and Janssen Pharmaceutica, have terminated their research collaboration and license agreement regarding the OX-CLI and OX-ESI programs.

A third, undisclosed Janssen program was also terminated. Each party has regained all commercial rights for its respective drug discovery programs. The OX-CLI and OX-ESI programs, focusing on discovering and developing innovative new treatments for asthma, chronic obstructive pulmonary disease and other inflammatory diseases, will be closed.

Latest stories

Previous article

Precision receives US patent related to engineered meganucleases

Next article

NanoViricides files FluCide pre-IND to FDA

Related stories

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »

MORE STORIES